| Multiple Myeloma

Sarclisa vs Tecvayli

Side-by-side clinical, coverage, and cost comparison for multiple myeloma.

Deep comparison between: Sarclisa vs Tecvayli with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsTecvayli has a higher rate of injection site reactions vs Sarclisa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Tecvayli but not Sarclisa, including UnitedHealthcare

Category

Sarclisa

Tecvayli

At A Glance

RouteIV infusion

FrequencyEvery 1-4 weeks

ClassCD38-directed cytolytic antibody

RouteSC injection

FrequencyWeekly to every 4 weeks

ClassBCMA-directed CD3 T-cell engager

Indications

Multiple Myeloma

Multiple Myeloma

Dosing

Multiple Myeloma (with pomalidomide and dexamethasone) 10 mg/kg IV weekly in cycle 1 (days 1, 8, 15, 22 of a 28-day cycle), then every 2 weeks (days 1, 15) from cycle 2 onward.

Multiple Myeloma (with carfilzomib and dexamethasone) 10 mg/kg IV weekly in cycle 1, then every 2 weeks from cycle 2 onward.

Multiple Myeloma (with bortezomib, lenalidomide, and dexamethasone) 10 mg/kg IV on days 1, 8, 15, 22, and 29 of cycle 1 (42-day cycle); every 2 weeks in cycles 2-17; every 4 weeks from cycle 18 onward.

Multiple Myeloma (combination with daratumumab and hyaluronidase-fihj) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 3), then 1.5 mg/kg once weekly (weeks 2-8), 3 mg/kg every 2 weeks (weeks 9-24), and 3 mg/kg every 4 weeks (week 25 onward); administer until disease progression or unacceptable toxicity.

Multiple Myeloma (monotherapy) SC step-up doses of 0.06 mg/kg (day 1) and 0.3 mg/kg (day 4), then 1.5 mg/kg once weekly; may reduce to 1.5 mg/kg every 2 weeks for patients with complete response or better maintained for at least 6 months.

Contraindications

Severe hypersensitivity to isatuximab-irfc or any of its excipients

—

Drug Interactions

188View drug interactions

27View drug interactions

Adverse Reactions

Most common (>=20%) Upper respiratory tract infection, infusion-related reactions, pneumonia, diarrhea, fatigue, hypertension, dyspnea, insomnia, bronchitis, cough, back pain, peripheral sensory neuropathy, musculoskeletal pain, cataract, constipation, peripheral edema, rash

Serious Pneumonia, upper respiratory tract infections, febrile neutropenia, cardiac failure

Most common (>=20%) pyrexia, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, diarrhea, hypogammaglobulinemia, cough, COVID-19, gastroenteritis, weight decreased

Serious pneumonia, cytokine release syndrome, sepsis, pyrexia, COVID-19, febrile neutropenia, gastroenteritis, acute kidney injury, encephalopathy, second primary malignancy

Pharmacology

Isatuximab-irfc is an IgG1-derived monoclonal antibody that binds to CD38 expressed on hematopoietic and tumor cells, inducing apoptosis and activating immune effector mechanisms including ADCC, ADCP, and CDC, while also inhibiting CD38 ADP-ribosyl cyclase activity and suppressing CD38-positive T-regulatory cells.

Teclistamab-cqyv is a bispecific T-cell engaging antibody that binds CD3 on T-cells and BCMA on multiple myeloma cells, activating T-cells to release proinflammatory cytokines and lyse myeloma cells.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Sarclisa